MedTrace Logo

Role of Non-Selective Beta-Adrenergic Blocker in Severe TBI

NCT06870370 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-11

No results posted yet for this study

Summary

The role of nonselective beta adrenergic blocker as antistress agent in severe traumatic brain injury

Conditions

  • Traumatic Brain Injury (TBI) Patients
  • Intracranial Pressure
  • Intensive Care Unit
  • Mortality

Interventions

DRUG

propranolol

This group Will receive propranolol intravenously at a dose of 1 mg every 6 h for 7 days, and doses will be held if heart rate less than 60 bpm, mean arterial pressure less than 65 mmHg

DRUG

normal saline IV

This group Will receive 1ml of sterile 0.9% normal saline IV every 6 hours for 7 days

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Huda Elkallaf, Resident · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-20
Primary Completion
2025-09-20
Completion
2025-09-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06870370 on ClinicalTrials.gov